EGFR and non-small cell lung carcinoma: However, it remains unknown which is the optimal treatment as the first-line regimen for these patients on overall survival (OS).<h4>Materials and methods</h4>Randomized controlled trials and meeting abstracts that investigated EGFR-TKIs alone or in combination as front-line care for patients with NSCLC were systematically searched in relevant databases and reviewed.